Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro

Aras Y., ERGÜVEN M., Aktas E., YAZIHAN N., Bilir A.

NEUROLOGICAL RESEARCH, cilt.38, sa.9, ss.766-774, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 9
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1080/01616412.2016.1203096
  • Dergi Adı: NEUROLOGICAL RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.766-774
  • Anahtar Kelimeler: Imatinib mesylate, Lithium chloride, Midkine, Glioblastoma, Antagonism, BETA-CATENIN, MIDKINE, INHIBITION, EXPRESSION, AUTOPHAGY, ACTIVATION, MECHANISMS, ARREST
  • Ankara Üniversitesi Adresli: Evet

Özet

Objectives: Glioblastoma (GBM), the most common primary tumour of the central nervous system, is characterised by a high malignancy and poor prognosis. The aims of this study were to investigate whether the combination of imatinib mesylate (IM) and lithium chloride (LiCl) exhibited a synergistic effect in treatment and to determine whether midkine (MK) affected the fate of this treatment in vitro.